Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

AM630

Catalog No: tcsc0854

Available Sizes

Size: 10mg

Size: 50mg

Size: 100mg

Specifications

CAS No:
164178-33-0

Formula:
$C_{23}H_{25}IN_2O_3$

Pathway:
GPCR/G Protein

Target:
Cannabinoid Receptor

Purity / Grade:
>98%

Solubility:
10 mM in DMSO

Observed Molecular Weight:
504.36

Product Description

AM630 is a selective **CB_2** antagonist with **K_i** of 31.2 nM, and displays 165-fold selectivity over CB_1 receptors.

IC50 & Target: Ki: 31.2 nM (CB_2)

In Vitro:

Web: www.taiclone.com
Tel: +886-2-2735-9682
Email: order@taiclone.com

The AM251 and AM630-evoked Ca^{2+} influxes into TG sensory neurons aere concentration-dependent, and fitted. The EC_{50} for AM251 and AM630 are 7.37 μM and 15.6 μM, respectively. AM251 and AM630 activate TRPA1 in TG sensory neurons. AM630 is comparable in value in both TRPA1 and TRPV1/TRPA1 expressing CHO cells (2 and 4.6 μM, respectively). AM251 and AM630 activation of TRPA1 is modulated by TRPV1[2]. AM630 (0, 50, 100, and 200 nM) is not toxic to RAW264.7 cells. AM630 (100 nM) substantially inhibits osteoclastogenesis in cultures with RANKL and Ti particles in a dose-dependent manner[3]. AM630 (1 μM) blocks the CP-55,940 dose response with EC_{50} of 170 nM at human and EC_{50} of 110 nM at rat cannabinoid CB2 receptor[4].

In Vivo: AM630 (2, 3 mg/kg, i.p.) significantly reduces the time spent in the light box compared with vehicle group. AM630 increases anxiety since the time spent in the light box is reduced compared with its corresponding control group. AM630 (1, 2 or 3 mg/kg, i.p., twice a day) produces a significant anxiolytic effect, increasing the time spent in the light box at all of the doses used[1].